Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy

NCT06976021 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer
Uterine Cervical Cancer
Uterine Corpus Cancer
Malignant Melanoma
Clear Cell Renal Cell Carcinoma

Interventions

DIAGNOSTIC_TEST: Baseline 89-Zr Pembrolizumab Immuno PET-CT
DIAGNOSTIC_TEST: Proteomic assay
DIAGNOSTIC_TEST: Follow-up 89-Zr Pembrolizumab Immuno PET-CT

Sponsor

Maria Sklodowska-Curie National Research Institute of Oncology